Projects
Horizon Europe - FIBROTARGET
EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD. This will allow vital future therapeutic...
EFCCA PROJECTS DIGEST Newsletter
The new issue of our PROJECTS DIGEST is now online!
Download it here: Issue #5 (November 2024)
We are delighted to present to you the EFCCA PROJECTS DIGEST. This newsletter will include information regarding the 5 Horizon Europe projects and 2 European projects supported by the Horizon 2020 initiative that EFCCA is presently engaged in. The PROJECTS DIGEST ...
Horizon Europe - METHYLOMIC
The METHYLOMIC project is advancing research to make personalised treatments for Crohn’s Disease (CD) and similar immune-mediated conditions a reality.
By building on previous studies, researchers have identified specific patterns in DNA methylation (a type of genetic marker) that can predict how well a patient will respond to certain biological therapies for CD. These markers, found in blood...
Horizon Europe - miGut
We take great pleasure in informing you that EFCCA is one of the 12 partners coming from 9 countries of the consortium for the miGut-Health Project, which has been selected for European funding under the Horizon Europe framework. This project will strive to empower people living with IBD by creating state-of-the-art strategies for early disease prediction, prevention, and health monitoring. This...
Innovative Medicines Initiative (IMI2) - IDEA-FAST
EFCCA is involved in this exciting project that will identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily living and Health-related quality of life (HRQoL) in ImmuneMediated Inflammatory Diseases such as IBD as well as other such as Rheumatoid Arthritis and Lupus and which will ultimately have a positive impact on the quality of life of these...
Patient Preferences
WHAT DO IBD PATIENTS FIND IMPORTANT IN THEIR TREATMENT?
“What do you find important in your (IBD?) treatment?”, “Which quality of life effects are important to you?”, “Which side-effects do you want to avoid?”, “Which characteristics should future drugs have according to you?”
To address these questions, EFCCA has embarked on exciting research with the University of Leuven (KU...
EFCCA Empowerment Academy
We launched our EFCCA Empowerment Academy, a training programme tailored for recent EFCCA members designed to offer deeper insights into the organisation.
The programme provides participants with a global learning journey led by EFCCA staff and other experts. Encompassing subjects like law, corporate governance, organisational history or ethics, it guarantees a comprehensive comprehension...
World IBD Day 2024
Join us in celebrating World IBD Day 2024!
A Global Movement for Accessible IBD Care
We are pleased to announce EFCCA's plans for World IBD Day 2024, united under the theme: "IBD Has No Borders."
This year, our focus is on strengthening global alliances and amplifying our collective impact in the fight against Inflammatory Bowel Disease (IBD...
World IBD Day
World IBD Day takes place on 19 May each year and unites people worldwide in their fight against Crohn's disease and ulcerative colitis, known as inflammatory bowel diseases (IBD).
This year our theme for World IBD Day is IBD HAS NO BORDERS : World IBD Day 2024
Purple Ribbon Awareness
Many of the IBD associations linked to World IBD Day are using the purple ribbon as a symbol of...
Horizon Europe - GlycanTrigger
The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with CD that will be translated into improved disease prediction and prevention. The project aims to do so by addressing how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms (...